For patients with non-PC, 24.2% (8/33) and 16.7% (6/36) of patients with CP and IPMN, respectively, were positive for the APOA2-i Index. This evidence concerns the gene APOA2 and pancreatic intraductal papillary-mucinous neoplasm.